Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Angiocrine Bioscience, Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The portfolio involves 3 distinct examiners and 3 distinct art units. MONTANARI, DAVID A is the busiest examiner, with 1 pending matter, so each pending matter is assigned through a separate examination channel.
A coordinated review of biotechnology and pharmaceutical terminology can support consistency across the filings, while each response should address its own examiner’s objections and technical record. Counsel can compare specification support and claim architecture before filing, but the data does not show a repeated examiner relationship. Portfolio oversight should therefore focus on timing, consistency, and separate response quality.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| ABBOTT, KODYE LEE | 1 | 54.5% | +71.4% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | SCHUBERG, LAURA J | 25d overdue |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | ABBOTT, KODYE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | SCHUBERG, LAURA J | 25d overdue |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1634 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | 1632 | §103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | SCHUBERG, LAURA J | 1631 | §103Other | Final Rejection | 25d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAngiocrine Bioscience, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David A Montanari has the most, with 1 of Angiocrine Bioscience, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
